300 filings
Page 5 of 15
8-K
aqq7y zd3
7 Jan 21
Oragenics Enters into Material Transfer Agreement with Adjuvance Technologies for COVID-19 Vaccine Adjuvant
7:22am
8-K
7rjcwmu1tfpn91h
29 Dec 20
Oragenics Announces Closing of $6.5 Million Registered Direct Offering
4:17pm
8-K
f2axuozob1jj13nj
28 Dec 20
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
5:04pm
8-K
n15ihu51b30ce30yjlv
24 Nov 20
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
11:59am
8-K
p0fqiwbdt7pl8
20 Nov 20
Oragenics Prices $5.25 Million Common Stock Offering
8:44am
8-K
hbrc64uecg0b1
19 Nov 20
Oragenics Announces Proposed Underwritten Public Offering
5:18pm
8-K
ecxj6 kxwnyvgq
10 Nov 20
Regulation FD Disclosure
4:35pm
8-K
znsigq6qhbbbd6
6 Oct 20
FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
7:48am
8-K
7uardp
28 Sep 20
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
7:45am
8-K
7g9l33v xm3
11 Sep 20
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
8:53am
8-K
wda2qj
24 Aug 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
4wv15jevrxm9dpq2h9tf
20 Aug 20
Other Events
8:54am
8-K
6vgzs
18 Aug 20
Regulation FD Disclosure
7:55am
8-K/A
xvzjwe4pwo3hv4
14 Aug 20
Financial Statements and Exhibits
4:22pm
8-K
tjhf81
27 Jul 20
Other Events
7:49am
8-K
i0f2x
22 Jul 20
Regulation FD Disclosure
7:58am
8-K
09glq 2u8yzh7
10 Jul 20
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
7:49am
8-K
re9afo38u0 yzcwrdn
5 Jun 20
Entry into a Material Definitive Agreement
4:00pm
8-K/A
ehj8quj7c7 v0
29 May 20
Audited Financial Statements
4:05pm
8-K
r0zf3pjbwjg2himh
8 May 20
Regulation FD Disclosure
7:00am